
  
    
      
        Background_NNP
        Vitamin_NNP E_NNP is_VBZ an_DT essential_JJ fat-soluble_JJ vitamin_NN ._. The_DT
        general_JJ term_NN vitamin_NN E_NNP refers_VBZ to_TO eight_CD naturally_RB occurring_VBG
        and_CC synthetic_JJ tocopherols_NNS and_CC tocotrienols_NNS and_CC their_PRP$
        acetate_NN and_CC succinate_NN derivatives_NNS ._. Although_IN the_DT naturally_RB
        occurring_VBG forms_NNS of_IN vitamin_NN E_NNP have_VBP lipid-soluble_JJ antioxidant_NN
        properties_NNS that_WDT protect_VBP cell_NN membranes_NNS against_IN damage_NN by_IN
        free_JJ radicals_NNS ,_, the_DT acetate_NN and_CC succinate_NN derivatives_NNS that_WDT
        are_VBP esterified_JJ at_IN the_DT C-_NNP 6_CD position_NN of_IN the_DT chromanol_NN ring_NN do_VBP
        not_RB have_VB antioxidant_NN properties_NNS unless_IN the_DT esterification_NN
        is_VBZ hydrolyzed_JJ and_CC free_JJ tocopherol_NN is_VBZ regenerated_JJ [_NN 1_CD 2_CD 3_CD ]_NN
        ._.
        Synthetic_NNP vitamin_NN E_NNP ,_, a_DT form_NN of_IN vitamin_NN E_NNP commonly_RB used_VBD
        as_IN a_DT dietary_JJ supplement_NN ,_, is_VBZ the_DT form_NN used_VBN in_IN the_DT 
        in_IN vivo_NN studies_NNS reported_VBD here_RB ._. It_PRP is_VBZ
        a_DT mixture_NN of_IN eight_CD stereoisomers_NNS in_IN equal_JJ amounts_NNS
        designated_VBN "_'' dl_NN "_'' or_CC all-rac_JJ tocopherol_NN and_CC does_VBZ have_VB
        antioxidant_NN properties_NNS [_NN 4_CD ]_NN ._. Thus_RB ,_, different_JJ forms_NNS of_IN
        vitamin_NN E_NNP can_MD have_VB different_JJ antioxidant_NN properties_NNS as_RB well_RB
        as_IN differences_NNS in_IN their_PRP$ absorption_NN ,_, distribution_NN ,_, and_CC
        metabolism_NN [_NN 4_CD ]_NN ._. There_EX are_VBP also_RB reports_VBZ that_IN some_DT forms_NNS
        of_IN vitamin_NN E_NNP have_VBP activity_NN against_IN cancer_NN cells_NNS 
        in_IN vitro_NN [_NN 3_CD 5_CD ]_NN ._. For_IN example_NN ,_,
        tocotrienol_NN and_CC vitamin_NN E_NNP succinate_NN are_VBP reported_VBN to_TO have_VB
        antiproliferative_JJ activity_NN in_IN human_JJ cancer_NN cells_NNS whereas_IN
        some_DT forms_NNS of_IN vitamin_NN E_NNP are_VBP reported_VBN to_TO induce_VB apoptosis_NNS in_IN
        cancer_NN cell_NN types_NNS but_CC not_RB in_IN normal_JJ cell_NN types_NNS [_NN 3_CD ]_NN ._.
        Specifically_RB ,_, these_DT apoptogenic_JJ forms_NNS include_VBP
        RRR-α-tocopheryl_NNP succinate_NN and_CC RRR-δ-tocopherol_NNP while_IN the_DT
        α_NN ,_, β_NN ,_, and_CC γ_NN tocopherol_NN and_CC acetate_NN derivatives_NNS of_IN
        tocopherol_NN were_VBD not_RB apoptogenic_JJ [_NN 3_CD ]_NN ._. There_EX are_VBP few_JJ
        reports_NNS on_IN the_DT use_NN of_IN vitamin_NN E_NNP for_IN treating_VBG tumorous_JJ
        cancers_NNS 
        in_IN vivo_NN but_CC the_DT results_NNS are_VBP
        inconsistent_JJ [_NN 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD ]_NN ._. It_PRP is_VBZ therefore_RB essential_JJ
        that_IN the_DT form_NN of_IN vitamin_NN E_NNP used_VBD in_IN any_DT research_NN study_NN as_RB
        well_RB as_IN the_DT dosage_NN and_CC the_DT mode_NN of_IN administration_NN be_VB
        defined_VBN ._.
        The_DT study_NN reported_VBD on_IN here_RB was_VBD originally_RB designed_VBN to_TO
        test_VB the_DT ability_NN of_IN a_DT high_JJ dietary_JJ dose_NN of_IN sE_NN to_TO prevent_VB
        lipid_NN peroxidation_NN in_IN nude_JJ mice_NNS bearing_VBG a_DT human_JJ breast_NN
        cancer_NN xenograft_NN MDA-MB-_NNP 231_CD [_NN 11_CD 12_CD ]_NN ._. To_TO assure_VB
        suppression_NN of_IN lipid_NN peroxidation_NN ,_, sE_NN was_VBD added_VBN to_TO the_DT diet_NN
        at_IN a_DT dose_NN level_NN ._. For_IN example_NN ,_, the_DT vitamin_NN E_NNP requirement_NN for_IN
        mice_NNS when_WRB all-rac-α-tocopherol_JJ acetate_NN is_VBZ used_VBN as_IN the_DT
        dietary_JJ source_NN is_VBZ 32_CD mg_NN /_NN kg_NN for_IN diets_NNS in_IN which_WDT lipids_NNS
        comprise_VBP less_JJR than_IN 10_CD percent_NN of_IN the_DT diet_NN [_NN 1_CD ]_NN ._. Thus_RB ,_, the_DT
        900_CD mg_NN /_NN kg_NN diet_NN used_VBN in_IN this_DT study_NN is_VBZ 28_CD fold_VB higher_JJR than_IN
        this_DT estimated_JJ requirement_NN ._. This_DT is_VBZ in_IN contrast_NN to_TO human_JJ
        recommendations_NNS which_WDT are_VBP given_VBN in_IN mg_NN of_IN α-tocopherol_JJ
        equivalents_NNS with_IN the_DT adult_JJ RDA_NNP set_VBD at_IN 15_CD mg_NN /_NN day_NN and_CC the_DT
        upper_JJ limit_NN set_VBN at_IN 1000_CD mg_NN /_NN day_NN ._. The_DT observed_VBN antitumor_NN
        activity_NN of_IN this_DT sE_NN dietary_JJ supplementation_NN was_VBD an_DT
        unexpected_JJ experimental_JJ result_NN as_IN sE_NN was_VBD not_RB previously_RB
        reported_VBD to_TO have_VB antitumor_NN activity_NN although_IN vitamin_NN E_NNP may_MD
        give_VB modest_JJ protection_NN against_IN the_DT risk_NN of_IN breast_NN cancer_NN [_NN
        5_CD ]_NN ._. Based_VBN on_IN the_DT observed_VBN antitumor_NN activity_NN of_IN high_JJ dose_NN
        sE_NN in_IN the_DT diet_NN ,_, it_PRP became_VBD important_JJ to_TO investigate_VB if_IN the_DT
        sE_NN supplement_NN ,_, when_WRB fed_VBN at_IN such_JJ a_DT high_JJ dose_NN ,_, was_VBD associated_VBN
        with_IN the_DT modification_NN of_IN the_DT fatty_NN acid_NN composition_NN of_IN
        mitochondrial_NN and_CC microsomal_NN membranes_NNS and_CC if_IN the_DT sE_NN was_VBD
        acting_VBG as_IN an_DT antioxidant_NN or_CC possibly_RB a_DT prooxidant_NN in_IN tumor_NN
        and_CC in_IN host_NN tissues_NNS ._. Given_VBN that_IN such_JJ a_DT high_JJ dose_NN of_IN sE_NN has_VBZ
        antitumor_NN activity_NN ,_, it_PRP also_RB became_VBD important_JJ to_TO look_VB for_IN
        possible_JJ side-effects_JJ in_IN host_NN tissues_NNS prior_RB to_TO further_VB
        preclinical_JJ trials_NNS ._.
      
      
        Results_NNS
        
          Tumor_NNP growth_NN
          The_DT mean_JJ tumor_NN growth_NN rate_NN was_VBD calculated_VBN using_VBG linear_JJ
          regression_NN analysis_NN of_IN mean_NN tumor_NN size_NN over_IN time_NN ._. After_IN
          two_CD weeks_NNS of_IN dietary_JJ intervention_NN ,_, the_DT mean_JJ growth_NN rate_NN
          of_IN the_DT group_NN of_IN mice_NNS fed_VBD the_DT sE_NN supplement_NN was_VBD half_NN that_IN
          of_IN mice_NNS not_RB fed_VBD the_DT sE_NN supplement_NN however_RB this_DT difference_NN
          was_VBD not_RB quite_RB significant_JJ at_IN the_DT p_NN <_NN 0_CD ._. 05_CD level_NN ._. Tumor_NNP
          growth_NN rate_NN in_IN mice_NNS not_RB sacrificed_JJ after_IN 2_CD weeks_NNS of_IN
          dietary_JJ intervention_NN was_VBD followed_VBN for_IN an_DT additional_JJ four_CD
          weeks_NNS ._. Analysis_NNP of_IN mean_NN tumor_NN growth_NN rate_NN for_IN the_DT entire_JJ
          42_CD days_NNS of_IN intervention_NN revealed_VBD that_IN the_DT mean_JJ tumor_NN
          growth_NN rate_NN of_IN mice_NNS fed_VBD the_DT sE_NN supplement_NN was_VBD 63_CD %_NN slower_JJR
          than_IN the_DT mean_JJ tumor_NN growth_NN rate_NN of_IN mice_NNS not_RB fed_VBD the_DT sE_NN
          supplement_NN (_( significant_JJ at_IN p_NN <_NN 0_CD ._. 01_CD as_IN illustrated_VBN in_IN
          Fig_NNP ._. 1_LS )_) ._.
        
        
          Lipid_NNP peroxidation_NN
          Tumor_NNP and_CC host_NN tissue_NN malondialdehyde_NN and_CC
          malondialdehyde_NN by-products_JJ were_VBD analyzed_VBN by_IN the_DT
          thiobarbituric_JJ acid_NN reactive_JJ substrates_NNS (_( TBARS_NNP )_) assay_NN to_TO
          estimate_VB the_DT extent_NN of_IN lipid_NN peroxidation_NN after_IN six_CD weeks_NNS
          of_IN intervention_NN ._. The_DT TBARS_NNP findings_NNS are_VBP summarized_VBD in_IN
          Fig_NNP ._. 2_LS ._. The_DT mean_JJ value_NN of_IN TBARS_NNP was_VBD significantly_RB (_( p_NN <_NN
          0_CD ._. 01_CD )_) lower_JJR in_IN the_DT tumor_NN and_CC in_IN the_DT liver_NN of_IN the_DT mice_NNS fed_VBD
          sE_NN but_CC was_VBD not_RB significantly_RB different_JJ (_( p_NN >_NN 0_CD ._. 05_CD )_) in_IN
          the_DT colon_NN ._.
        
        
          Fatty_NNP acid_NN composition_NN of_IN microsomal_NN and_CC of_IN
          mitochondrial_NN membranes_NNS
          Data_NNS on_IN the_DT percent_NN of_IN the_DT total_JJ fatty_NN acid_NN
          composition_NN for_IN linoleic_JJ acid_NN (_( LA_NNP )_) ,_, for_IN arachidonic_JJ acid_NN
          (_( AA_NN )_) ,_, and_CC for_IN docosahexanoic_JJ acid_NN (_( DHA_NNP )_) in_IN the_DT microsomal_NN
          and_CC in_IN the_DT mitochondrial_NN fractions_NNS of_IN tumor_NN ,_, of_IN liver_NN ,_,
          and_CC of_IN colon_NN after_IN two_CD weeks_NNS of_IN dietary_JJ intervention_NN both_DT
          with_IN and_CC without_IN sE_NN supplementation_NN are_VBP summarized_VBD in_IN
          Table_NNP 1_CD ._. The_DT mean_NN levels_NNS of_IN LA_NNP were_VBD lower_JJR in_IN both_DT
          microsomal_NN and_CC mitochondrial_NN fractions_NNS of_IN the_DT tumor_NN ,_, the_DT
          liver_NN ,_, and_CC the_DT colon_NN of_IN mice_NNS fed_VBD sE_NN than_IN in_IN mice_NNS without_IN
          the_DT sE_NN ._. That_DT 6_CD of_IN 6_CD mean_VB values_NNS of_IN LA_NNP were_VBD lower_JJR with_IN sE_NN
          supplementation_NN indicates_VBZ a_DT consistent_JJ pattern_NN of_IN
          membrane_NN LA_NNP composition_NN change_NN in_IN the_DT tumor_NN and_CC in_IN the_DT
          host_NN tissues_NNS ._. Conversely_RB ,_, the_DT mean_JJ level_NN of_IN DHA_NNP was_VBD
          higher_JJR in_IN the_DT microsomal_NN and_CC mitochondrial_NN fractions_NNS of_IN
          the_DT tumor_NN ,_, the_DT liver_NN ,_, and_CC the_DT colon_NN of_IN mice_NNS fed_VBD sE_NN than_IN
          in_IN mice_NNS without_IN the_DT sE_NN supplement_NN ._. That_DT 6_CD of_IN 6_CD mean_VB
          values_NNS of_IN DHA_NNP were_VBD higher_JJR with_IN sE_NN supplementation_NN
          indicates_VBZ a_DT consistent_JJ pattern_NN of_IN membrane_NN DHA_NNP change_NN in_IN
          the_DT tumor_NN and_CC in_IN the_DT host_NN tissues_NNS ._. The_DT mean_JJ level_NN of_IN AA_NN
          in_IN the_DT membrane_NN fractions_NNS of_IN the_DT three_CD tissues_NNS was_VBD not_RB
          consistently_RB changed_VBN ._.
          To_TO further_VB explore_VB the_DT effect_NN of_IN sE_NN supplementation_NN on_IN
          membrane_NN fatty_NN acid_NN composition_NN ,_, the_DT relative_JJ level_NN of_IN
          each_DT of_IN the_DT three_CD fatty_NN acids_NNS in_IN each_DT fraction_NN of_IN each_DT
          tissue_NN was_VBD expressed_VBN as_IN a_DT ratio_NN of_IN the_DT level_NN with_IN sE_NN
          supplement_NN over_IN the_DT level_NN without_IN sE_NN supplement_NN ._. The_DT
          results_NNS of_IN this_DT exercise_NN are_VBP plotted_VBD in_IN Fig_NNP ._. 3_LS ._. The_DT ratio_NN
          is_VBZ consistently_RB lower_JJR than_IN unity_NN for_IN LA_NNP (_( mean_VB 0_CD ._. 70_CD )_) and_CC
          consistently_RB higher_JJR than_IN unity_NN for_IN DHA_NNP (_( mean_VB 4_CD ._. 9_CD )_) ._. The_DT
          mean_JJ ratio_NN for_IN AA_NN was_VBD near_IN one_CD ,_, indicating_VBG no_DT significant_JJ
          difference_NN ._.
        
        
          Body_NN weight_NN
          Data_NNS on_IN change_NN in_IN body_NN weights_NNS at_IN two_CD weeks_NNS and_CC at_IN six_CD

          weeks_NNS from_IN the_DT body_NN weight_NN at_IN the_DT start_NN of_IN dietary_JJ
          intervention_NN are_VBP summarized_VBD in_IN Table_NNP 2_CD ._. The_DT mean_NN values_NNS
          for_IN change_NN in_IN body_NN weights_NNS at_IN two_CD or_CC at_IN six_CD weeks_NNS are_VBP not_RB
          significantly_RB different_JJ due_NN to_TO diet_NN ._. The_DT body_NN weight_NN loss_NN
          observed_VBD at_IN six_CD weeks_NNS can_MD be_VB attributed_VBN to_TO the_DT presence_NN
          of_IN the_DT growing_VBG tumor_NN ._.
        
        
          Blood_NNP counts_NNS
          Results_NNS of_IN blood_NN counts_VBZ ,_, as_IN summarized_VBD in_IN Table_NNP 3_CD ,_,
          reveal_VBP no_DT significant_JJ differences_NNS in_IN white_JJ cell_NN (_( WBC_NNP )_) ,_, in_IN
          red_JJ blood_NN cell_NN (_( RBC_NNP )_) or_CC in_IN platelet_NN (_( PLT_NNP )_) numbers_NNS due_JJ to_TO
          two_CD weeks_NNS of_IN sE_NN supplementation_NN ._.
        
        
          Colon_NN histology_NN
          Colon_NN crypt_NN height_NN expressed_VBD in_IN number_NN of_IN cells_NNS from_IN
          the_DT crypt_NN base_NN to_TO the_DT crypt_NN mouth_NN was_VBD scored_VBN as_IN an_DT
          indicator_NN of_IN damage_NN attributable_JJ to_TO sE_NN supplementation_NN ._.
          The_DT crypt_NN column_NN heights_NNS ,_, (_( number_NN of_IN cells_NNS ,_, mean_VB ±_NN SE_NNP )_)
          was_VBD 21_CD ._. 24_CD ±_NN 0_CD ._. 54_CD (_( 15_CD )_) for_IN mice_NNS without_IN the_DT sE_NN
          supplementation_NN and_CC 21_CD ._. 63_CD ±_NN 0_CD ._. 51_CD (_( 11_CD )_) for_IN mice_NNS with_IN the_DT
          sE_NN supplementation_NN ._. These_DT means_NNS are_VBP not_RB significantly_RB
          different_JJ ._. No_DT histological_JJ differences_NNS attributable_JJ to_TO
          the_DT dietary_JJ intervention_NN with_IN sE_NN were_VBD observed_VBN ._.
        
        
          Heart_NNP histopathology_NN and_CC antioxidant_NN enzyme_NN gene_NN
          expression_NN
          Histological_NNP cross-sections_JJ of_IN the_DT heart_NN taken_VBN
          one-third_NN of_IN the_DT distance_NN from_IN the_DT apex_NN were_VBD studied_VBN for_IN
          indications_NNS of_IN side-effects_JJ of_IN high_JJ dietary_JJ levels_NNS of_IN sE_NN ._.
          Vacuole_NNP formation_NN in_IN the_DT cardiac_JJ myocytes_NNS has_VBZ been_VBN used_VBN
          as_IN a_DT marker_NN of_IN cardiotoxicity_NN [_NN 13_CD ]_NN ._. The_DT mean_JJ percent_NN
          of_IN cardiac_JJ myocytes_NNS with_IN one_CD or_CC more_JJR vacuoles_NNS in_IN the_DT
          subendocardial_NN myocytes_NNS of_IN the_DT left_NN ventricle_NN was_VBD
          significantly_RB (_( p_NN <_NN 0_CD ._. 05_CD )_) higher_JJR in_IN mice_NNS fed_VBD the_DT sE_NN
          supplement_NN (_( Fig_NNP ._. 4_LS )_) ._. Based_VBN on_IN this_DT indication_NN of_IN
          cardiotoxicity_NN ,_, the_DT remaining_VBG portion_NN of_IN the_DT heart_NN that_WDT
          had_VBD been_VBN snap_NN frozen_VBN in_IN liquid_JJ nitrogen_NN at_IN the_DT time_NN of_IN
          sacrifice_NN was_VBD used_VBN to_TO look_VB for_IN differences_NNS in_IN expression_NN
          of_IN antioxidant_NN genes_NNS using_VBG quantitative_JJ RT_NNP PCR_NNP
          methodology_NN ._.
          The_DT results_NNS of_IN the_DT RT_NNP PCR_NNP findings_NNS are_VBP summarized_VBD in_IN
          Table_NNP 4_CD ._. Of_IN the_DT antioxidant_NN enzyme_NN mRNAs_NNS measured_VBN ,_, the_DT
          only_JJ mRNA_NN that_WDT differed_VBD significantly_RB due_JJ to_TO diet_NN was_VBD the_DT
          inducible_JJ form_NN of_IN heme_NN oxygenase_NN ,_, which_WDT is_VBZ identical_JJ to_TO
          heat_VB shock_NN protein_NN 32_CD ._. A_DT complete_JJ set_NN of_IN data_NNS was_VBD taken_VBN
          on_IN each_DT heart_NN ,_, which_WDT allowed_VBD calculation_NN of_IN the_DT ratio_NN of_IN
          each_DT antioxidant_NN gene_NN transcript_NN to_TO each_DT of_IN the_DT other_JJ
          gene_NN transcripts_NNS ._. The_DT results_NNS of_IN this_DT ratio_NN analysis_NN
          reveal_VB that_IN the_DT feeding_NN of_IN sE_NN supplement_NN caused_VBD the_DT ratio_NN
          of_IN MnSOD_NNP over_IN GPX-_NNP 1_CD to_TO significantly_RB increase_VB (_( see_VB Table_NNP
          4_LS )_) ._.
        
        
          Assay_NNP for_IN chromosomal_NN breakage_NN or_CC loss_NN
          The_DT presence_NN of_IN one_CD or_CC more_JJR micronuclei_NN in_IN peripheral_JJ
          erythrocytes_NNS in_IN mice_NNS is_VBZ an_DT accepted_VBN marker_NN of_IN chromosomal_NN
          breakage_NN or_CC loss_NN that_WDT occurred_VBD prior_RB to_TO the_DT extrusion_NN of_IN
          the_DT nucleus_NN during_IN erythrocyte_NN differentiation_NN ._. Results_NNS
          of_IN the_DT scoring_VBG of_IN the_DT numbers_NNS of_IN peripheral_JJ erythrocytes_NNS
          with_IN and_CC without_IN a_DT micronucleus_JJ are_NN summarized_VBD in_IN Table_NNP
          5_CD ._. Included_VBN in_IN Table_NNP 5_CD are_VBP data_NNS from_IN mice_NNS treated_VBN with_IN a_DT
          series_NN of_IN injections_NNS of_IN doxorubicin_NN ._. Doxorubicin_NNP (_( DOX_NNP )_) is_VBZ
          a_DT cytotoxic_JJ drug_NN with_IN prooxidant_NN properties_NNS known_VBN to_TO
          cause_VB genotoxic_JJ damage_NN resulting_VBG in_IN an_DT increase_NN in_IN number_NN
          of_IN erythrocytes_NNS with_IN a_DT micronucleus_JJ ._. The_DT results_NNS from_IN the_DT
          DOX_NNP treated_VBD mice_NNS served_VBD as_IN a_DT positive_JJ control_NN ._. Results_NNS of_IN
          statistical_JJ analyses_NNS demonstrate_VBP a_DT significant_JJ increase_NN
          in_IN erythrocytes_NNS with_IN micronuclei_NN due_JJ to_TO DOX_NNP treatment_NN but_CC
          no_DT significant_JJ difference_NN due_JJ to_TO sE_NN supplementation_NN ._. Note_VB
          that_IN the_DT highest_JJS mean_NN incidence_NN of_IN micronuclei_NN occurred_VBD
          in_IN the_DT group_NN of_IN mice_NNS fed_VBD the_DT sE_NN supplement_NN and_CC treated_VBN
          with_IN DOX_NNP ._.
        
      
      
        Discussion_NNP
        Vitamin_NNP E_NNP was_VBD established_VBN as_IN an_DT essential_JJ micronutrient_NN
        for_IN proper_JJ fetal_JJ development_NN [_NN 1_CD ]_NN and_CC the_DT amount_NN of_IN
        vitamin_NN E_NNP required_VBD to_TO maintain_VB proper_JJ fetal_JJ development_NN has_VBZ
        been_VBN defined_VBN in_IN International_NNP Units_NNS ._. In_IN addition_NN to_TO its_PRP$
        role_NN in_IN reproduction_NN ,_, vitamin_NN E_NNP is_VBZ known_VBN to_TO be_VB a_DT
        lipid-soluble_JJ antioxidant_NN that_IN blocks_NNS peroxidation_NN of_IN
        polyunsaturated_JJ fatty_NN acids_NNS in_IN cellular_JJ membranes_NNS and_CC is_VBZ
        known_VBN to_TO stabilize_VB biological_JJ membranes_NNS [_NN 14_CD 15_CD 16_CD 17_CD ]_NN ._.
        Because_IN vitamin_NN E_NNP has_VBZ multiple_JJ biological_JJ activities_NNS ,_, it_PRP is_VBZ
        best_JJS to_TO report_VB dosage_NN in_IN weight_NN units_NNS ._. The_DT recommended_VBD
        dietary_JJ allowance_NN and_CC tolerable_JJ upper_JJ intake_NN limit_NN for_IN sE_NN ,_,
        the_DT commercially_RB available_JJ form_NN ,_, has_VBZ been_VBN calculated_VBN to_TO be_VB
        about_IN 22_CD and_CC 1470_CD mg_NN per_IN day_NN respectively_RB for_IN 70_CD kg_NN adult_NN
        humans_NNS [_NN 1_CD ]_NN ._.
        In_IN animal_NN species_NNS ,_, oral_JJ intake_NN of_IN up_IN to_TO 200_CD mg_NN /_NN kg_NN body_NN
        weight_NN per_IN day_NN was_VBD reported_VBN not_RB to_TO result_VB in_IN noticeable_JJ
        side_NN effects_NNS [_NN 18_CD ]_NN ._. Thus_RB ,_, we_PRP selected_VBD to_TO use_VB a_DT dietary_JJ
        dose_NN of_IN sE_NN at_IN the_DT level_NN of_IN 200_CD mg_NN /_NN kg_NN body_NN weight_NN per_IN day_NN in_IN
        tumor_NN bearing_NN mice_NNS in_IN an_DT attempt_NN to_TO maximize_VB inhibition_NN of_IN
        lipid_NN peroxidation_NN in_IN the_DT cellular_JJ membranes_NNS of_IN the_DT tumor_NN
        without_IN an_DT expectation_NN of_IN finding_VBG harmful_JJ side-effects_JJ ._.
        Specifically_RB ,_, this_DT experiment_NN was_VBD originally_RB designed_VBN to_TO
        test_VB the_DT hypothesis_NNS that_IN DOX_NNP ,_, a_DT prooxidative_JJ cancer_NN
        chemotherapeutic_JJ drug_NN ,_, inhibits_NNS tumor_NN growth_NN by_IN increasing_VBG
        lipid_NN peroxidation_NN products_NNS in_IN the_DT tumor_NN to_TO cytostatic_JJ or_CC
        cytotoxic_JJ levels_NNS and_CC that_DT suppression_NN of_IN lipid_NN peroxidation_NN
        by_IN sE_NN would_MD suppress_VB the_DT antitumor_NN effects_NNS of_IN DOX_NNP [_NN 11_CD 12_CD ]_NN
        ._. The_DT results_NNS demonstrated_VBN that_DT sE_NN supplementation_NN did_VBD
        markedly_RB suppress_VB DOX-induced_NNP lipid_NN peroxidation_NN ,_, yet_RB tumor_NN
        growth_NN was_VBD still_RB suppressed_VBN in_IN mice_NNS treated_VBN with_IN DOX_NNP and_CC
        sE_NN ._. It_PRP was_VBD concluded_VBN that_WDT increased_VBN levels_NNS of_IN lipid_NN
        peroxidation_NN products_NNS were_VBD not_RB the_DT sole_JJ cause_NN of_IN tumor_NN
        growth_NN inhibition_NN by_IN DOX_NNP ._. As_IN reported_VBD here_RB (_( Fig_NNP ._. 1_LS )_) ,_, the_DT
        dietary_JJ supplementation_NN with_IN this_DT high_JJ dose_NN of_IN sE_NN ,_, by_IN
        itself_PRP ,_, retarded_JJ tumor_NN growth_NN to_TO a_DT significant_JJ extent_NN ._.
        It_PRP is_VBZ not_RB known_VBN how_WRB such_JJ a_DT high_JJ intake_NN of_IN sE_NN works_VBZ to_TO
        suppress_VB tumor_NN growth_NN ._. What_WP is_VBZ known_VBN from_IN the_DT current_JJ study_NN
        is_VBZ that_IN the_DT sE_NN supplement_NN reduced_VBD lipid_NN peroxidation_NN (_( Fig_NNP ._.
        1_LS )_) and_CC preferentially_RB stabilized_VBN membrane_NN polyunsaturated_JJ
        fatty_NN acids_NNS with_IN more_RBR double_JJ bonds_NNS (_( Fig_NNP ._. 3_LS )_) ._. It_PRP has_VBZ been_VBN
        proposed_VBN that_DT vitamin_NN E_NNP may_MD incorporate_VB into_IN cellular_JJ
        membranes_NNS by_IN association_NN of_IN the_DT tocopherol_NN side_NN chain_NN with_IN
        the_DT polyenoic_JJ fatty_NN acid_NN residues_NNS in_IN the_DT membrane_NN fatty_NN
        acids_NNS [_NN 15_CD 19_CD ]_NN ._. This_DT interaction_NN may_MD stabilize_VB cell_NN
        membranes_NNS by_IN making_VBG highly_RB unsaturated_JJ fatty_NN acids_NNS less_RBR
        liable_JJ to_TO peroxidation_NN as_RB well_RB as_IN by_IN making_VBG highly_RB
        unsaturated_JJ fatty_NN acids_NNS less_RBR available_JJ for_IN phospholipid_NN
        hydrolysis_NNS by_IN phospholipase_NN [_NN 15_CD 16_CD ]_NN ._. The_DT latter_JJ action_NN
        may_MD reduce_VB mobilization_NN of_IN arachidonic_JJ acid_NN (_( AA_NN )_) from_IN the_DT
        membranes_NNS and_CC in_IN this_DT way_NN reduce_VBP the_DT amount_NN of_IN AA_NN available_JJ
        as_IN a_DT substrate_NN to_TO cyclooxygenase_NN and_CC /_NN or_CC lipoxygenase_NN to_TO
        produce_VB eicosanoids_NNS with_IN mitogenic_JJ and_CC with_IN inflammatory_JJ
        properties_NNS [_NN 17_CD 20_CD ]_NN ._. Other_JJ possible_JJ antitumor_NN actions_NNS
        include_VBP :_: induction_NN of_IN apoptosis_NNS ,_, interference_NN with_IN hormone_NN
        production_NN ,_, modulation_NN of_IN cellular_JJ signaling_VBG and_CC gene_NN
        transcription_NN ,_, and_CC induction_NN of_IN differentiation_NN [_NN 4_CD 21_CD 22_CD
        23_CD 24_CD ]_NN ._.
        In_IN comparison_NN to_TO the_DT inhibitory_NN effect_NN of_IN vitamin_NN E_NNP on_IN
        mammary_JJ tumor_NN growth_NN (_( this_DT report_NN )_) ,_, Cognault_NNP et_CC al_NN ._. report_NN
        a_DT stimulatory_NN effect_NN of_IN vitamin_NN E_NNP on_IN mammary_JJ tumor_NN growth_NN ._.
        Specifically_RB ,_, Cognault_NNP et_CC al_NN ._. report_NN that_IN when_WRB the_DT diet_NN was_VBD
        high_JJ in_IN omega-_NN 3_CD PUFAs_NNP ,_, tumor_NN growth_NN was_VBD significantly_RB
        increased_VBN by_IN vitamin_NN E_NNP supplementation_NN ._. However_RB ,_, when_WRB the_DT
        diet_NN was_VBD relatively_RB low_JJ in_IN omega-_NN 3_CD PUFAs_NNP ,_, the_DT promotional_JJ
        effect_NN of_IN vitamin_NN E_NNP was_VBD not_RB observed_VBN [_NN 8_CD ]_NN ._. It_PRP is_VBZ
        noteworthy_JJ that_IN the_DT diet_NN used_VBN in_IN the_DT presently_RB reported_VBN
        study_NN was_VBD very_RB low_JJ in_IN omega-_NN 3_CD PUFAs_NNP and_CC that_IN this_DT diet_NN ,_,
        combined_VBN with_IN the_DT high_JJ dietary_JJ level_NN of_IN sE_NN ,_, resulted_VBD in_IN
        suppression_NN of_IN tumor_NN growth_NN ._. Thus_RB ,_, the_DT different_JJ results_NNS
        may_MD be_VB attributable_JJ to_TO the_DT type_NN and_CC the_DT amount_NN of_IN omega-_NN 3_CD
        polyunsaturated_JJ fatty_NN acids_NNS (_( PUFAs_NNP )_) in_IN the_DT diet_NN ._.
        Evidence_NN for_IN cardiotoxicity_NN ,_, as_IN observed_VBN in_IN this_DT study_NN ,_,
        was_VBD not_RB expected_VBN as_IN supplementation_NN with_IN vitamin_NN E_NNP at_IN
        extremely_RB high_JJ doses_NNS gave_VBD no_DT significant_JJ indications_NNS of_IN
        harmful_JJ side-effects_JJ in_IN animals_NNS or_CC in_IN humans_NNS [_NN 18_CD 25_CD ]_NN ._.
        Perhaps_RB vitamin_NN E_NNP supplementation_NN acts_NNS to_TO inhibit_VB lipid_NN
        peroxidation_NN but_CC at_IN the_DT same_JJ time_NN acts_NNS to_TO down_RB regulate_VB
        other_JJ protective_JJ antioxidant_NN systems_NNS as_IN suggested_VBN by_IN the_DT
        antioxidant_NN enzyme_NN gene_NN expression_NN data_NNS in_IN Table_NNP 4_CD ._. If_IN gene_NN
        expression_NN levels_NNS in_IN Table_NNP 4_CD reflect_VB antioxidant_NN enzyme_NN
        activity_NN ,_, then_RB an_DT increase_NN in_IN SOD_NNP and_CC decrease_VB in_IN GPX_NNP
        without_IN an_DT increase_NN in_IN CAT_NNP would_MD result_VB in_IN accumulation_NN of_IN
        inorganic_JJ and_CC organic_JJ peroxides_NNS and_CC hydroperoxides_NNS that_WDT can_MD
        react_VB with_IN Fe_NNP 2_CD +_NN to_TO yield_VB highly_RB reactive_JJ free_JJ radical_JJ
        products_NNS that_WDT can_MD damage_VB cellular_JJ proteins_NNS and_CC DNA_NNP as_RB well_RB
        as_IN lipids_NNS ._. Likewise_RB ,_, the_DT sE_NN supplementation_NN used_VBN caused_VBN low_JJ
        expression_NN of_IN the_DT stress-induced_JJ isoform_NN of_IN heme_NN oxygenase_NN ,_,
        (_( HO-_NNP 1_LS )_) ._. HO-_NNP 1_CD catalyzes_NNS the_DT breakdown_NN of_IN prooxidant_NN heme_NN to_TO
        biliverdin_NN with_IN release_NN of_IN carbon_NN monoxide_NN and_CC iron_NN ion_NN ._. It_PRP
        should_MD be_VB realized_VBN that_IN these_DT observations_NNS are_VBP suggestive_JJ
        of_IN cardiotoxicity_NN but_CC are_VBP not_RB definitive_JJ ._.
        Early_RB studies_VBZ suggested_VBD that_DT vitamin_NN E_NNP lessened_JJ the_DT
        cardiotoxic_JJ effects_NNS of_IN DOX_NNP chemotherapy_NN [_NN 26_CD ]_NN whereas_IN
        other_JJ studies_NNS indicate_VBP potentiation_NN of_IN DOX_NNP induced_VBD
        cardiotoxicity_NN [_NN 27_CD 28_CD ]_NN ._. Shinoyawa_NNP et_CC al_NN ._. [_NN 28_CD ]_NN suggest_VBP
        that_DT vitamin_NN E_NNP ,_, when_WRB combined_VBN with_IN DOX_NNP ,_, may_MD increase_VB levels_NNS
        of_IN toxic_JJ products_NNS in_IN the_DT heart_NN and_CC in_IN the_DT tumor_NN while_IN Liu_NNP
        and_CC Tan_NNP [_NN 27_CD ]_NN suggest_VBP that_DT vitamin_NN E_NNP may_MD have_VB prooxidant_NN
        properties_NNS at_IN high_JJ dosage_NN levels_NNS ._.
        The_DT micronuclei_NN results_NNS in_IN Table_NNP 5_CD suggest_VBP that_IN while_IN sE_NN
        protects_VBZ against_IN lipid_NN peroxidation_NN ,_, it_PRP did_VBD not_RB protect_VB the_DT
        genome_NN of_IN erythroblasts_NNS against_IN the_DT prooxidant_NN effects_NNS of_IN
        DOX_NNP in_IN this_DT study_NN ._. Thus_RB ,_, while_IN the_DT toxic_JJ effect_NN of_IN DOX_NNP was_VBD
        not_RB significantly_RB enhanced_VBN by_IN vitamin_NN E_NNP supplementation_NN ,_,
        neither_DT was_VBD the_DT toxic_JJ effect_NN of_IN DOX_NNP lessened_JJ by_IN vitamin_NN E_NNP
        supplementation_NN ._.
      
      
        Conclusion_NNP
        The_DT adage_NN that_IN more_JJR is_VBZ better_JJR may_MD not_RB hold_VB true_JJ for_IN
        vitamin_NN E_NNP as_IN there_EX may_MD be_VB beneficial_JJ effects_NNS at_IN certain_JJ
        levels_NNS but_CC not_RB at_IN high_JJ levels_NNS ._. Clearly_RB ,_, more_JJR research_NN is_VBZ
        needed_VBN on_IN the_DT antitumor_NN effects_NNS of_IN sE_NN but_CC caution_NN is_VBZ
        advised_VBN that_DT sE_NN may_MD also_RB have_VB side-effects_JJ in_IN the_DT
        heart_NN ._.
      
      
        Methods_NNP and_CC Materials_NNPS
        
          Diet_NNP components_NNS ,_, chemicals_NNS and_CC composition_NN
          Purified_NNP high_JJ nitrogen_NN casein_NN ,_, pure_JJ cornstarch_NN ,_,
          Alphacel_NNP (_( non-nutritive_JJ bulk_NN cellulose_NN )_) ,_, AIN-_NNP 76_CD vitamin_NN
          mixture_NN ,_, AIN-_NNP 76_CD mineral_NN mixture_NN and_CC choline_NN bitartrate_NN
          (_( 99_CD %_NN pure_JJ )_) were_VBD obtained_VBN from_IN ICN_NNP Nutritional_NNP
          Biochemicals_NNP ,_, Cleveland_NNP ,_, OH_NNP ._. Imperial_JJ brand_NN (_( Sugarland_NNP ,_,
          TX_NNP )_) extra_JJ fine_NN pure_JJ cane_NN sugar_NN and_CC 100_CD %_NN pure_JJ corn_NN oil_NN
          (_( Wesson_NNP )_) were_VBD purchased_VBN locally_RB ._. D_NNP ._. L_NNP ._. methionine_NN was_VBD
          purchased_VBN from_IN Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP ._. Corn_NN oil_NN contains_VBZ
          about_IN 50_CD %_NN linoleic_JJ acid_NN ,_, 23_CD %_NN oleic_JJ acid_NN ,_, 10_CD %_NN C_NNP 16_CD fatty_NN
          acids_NNS and_CC <_NN 1_CD %_NN n-_NN 3_CD PUFAs_NNP ._. The_DT composition_NN of_IN the_DT diet_NN
          was_VBD as_IN follows_VBZ :_: 5_CD %_NN corn_NN oil_NN ,_, 50_CD %_NN sugar_NN ,_, 20_CD %_NN casein_NN ,_, 15_CD %_NN
          cornstarch_NN ,_, 1_CD %_NN AIN-_NNP 76_CD vitamin_NN mix_NN (_( the_DT mix_NN contains_VBZ 20_CD
          g_SYM /_NN kg_NN of_IN dl-α-tocopherol_JJ acetate_NN )_) ,_, 3_CD ._. 5_CD %_NN AIN-_NNP 76_CD mineral_NN
          mix_NN ,_, 0_CD ._. 2_CD %_NN choline_NN bitartrate_NN ,_, 0_CD ._. 3_CD %_NN D_NNP ._. L_NNP ._. methionine_NN ,_, and_CC
          5_CD %_NN Alphacel_NNP fiber_NN [_NN 12_CD ]_NN ._.
        
        
          Histological_NNP analyses_NNS of_IN heart_NN and_CC colon_NN
          At_IN sacrifice_NN ,_, the_DT heart_NN and_CC colon_NN were_VBD removed_VBN ._. The_DT
          heart_NN was_VBD crosscut_NN through_IN the_DT ventricles_NNS 1_CD /_NN 3_CD of_IN the_DT
          distance_NN between_IN the_DT apex_NN and_CC the_DT atrium_NN ,_, and_CC then_RB the_DT
          apex_NN section_NN was_VBD fixed_VBN in_IN OmniFix_NNP II_NNP (_( Mt_NNP ._. Vernon_NNP ,_, NY_NNP )_) and_CC
          then_RB embedded_VBN ,_, cut_VB surface_NN down_RB ,_, in_IN molten_NN paraffin_NN ._. This_DT
          provided_VBD a_DT consistent_JJ histological_JJ section_NN for_IN estimates_NNS
          of_IN myocyte_NN vacuolization_NN and_CC toxicity_NN ._. Four_CD μm_NN thick_JJ
          sections_NNS were_VBD stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ._. The_DT
          number_NN of_IN myocytes_NNS with_IN vacuoles_NNS in_IN the_DT subendocardial_NN
          region_NN of_IN the_DT left_NN ventricle_NN was_VBD counted_VBN ._. Cross_NNP sections_NNS
          of_IN the_DT descending_VBG colon_NN were_VBD scores_NNS for_IN number_NN of_IN cells_NNS
          in_IN a_DT crypt_NN column_NN from_IN crypt_NN base_NN to_TO mouth_NN ._.
        
        
          Blood_NNP counts_NNS
          Blood_NNP was_VBD obtained_VBN by_IN cardiac_JJ puncture_NN at_IN sacrifice_NN
          and_CC assayed_JJ within_IN 3_CD hours_NNS of_IN collection_NN ._. A_DT Coulter_NNP STKS_NNP
          hematology_NN analyzer_NN was_VBD used_VBN for_IN counts_NNS of_IN red_JJ blood_NN
          cells_NNS ,_, white_JJ blood_NN cells_NNS ,_, and_CC platelets_NNS in_IN EDTA_NNP
          anticoagulated_JJ blood_NN of_IN the_DT mice_NNS ._.
        
        
          Micronucleus_NNP assay_NN
          At_IN the_DT time_NN of_IN necropsy_NN ,_, blood_NN was_VBD collected_VBN by_IN heart_NN
          puncture_NN using_VBG a_DT 1_CD ml_NN syringe_NN fitted_JJ with_IN a_DT 22_CD G_NNP needle_NN ._.
          Immediately_RB ,_, small_JJ drops_NNS of_IN blood_NN were_VBD placed_VBN on_IN clean_VB
          microscopic_JJ slides_NNS ._. The_DT blood_NN was_VBD pushed_VBN behind_IN another_DT
          slide_NN held_VBN at_IN a_DT 45_CD °_NN angle_NN to_TO form_VB a_DT thin_JJ smear_NN over_IN an_DT
          area_NN of_IN 3_CD -_: 4_CD cm_NN ._. All_DT smears_NNS were_VBD air-dried_JJ for_IN 30_CD -_: 45_CD
          minutes_NNS ._. The_DT cells_NNS on_IN the_DT slides_NNS were_VBD fixed_VBN in_IN absolute_JJ
          methanol_NN for_IN 30_CD minutes_NNS ._. All_DT slides_NNS were_VBD air-dried_JJ and_CC
          stored_VBD in_IN a_DT box_NN kept_VBD in_IN a_DT dark_JJ place_NN at_IN room_NN temperature_NN
          or_CC at_IN 4_CD °_NN C_NNP ._. The_DT slides_NNS were_VBD stained_JJ with_IN acridine_NN orange_NN
          before_IN microscopic_JJ evaluation_NN ._.
          All_DT slides_NNS were_VBD examined_VBN under_IN 1000_CD ×_NN magnification_NN
          using_VBG a_DT fluorescent_NN microscope_NN fitted_JJ with_IN appropriate_JJ
          filters_NNS for_IN acridine_NN orange_NN stain_VB ._. For_IN each_DT animal_NN ,_, the_DT
          percentage_NN of_IN 1000_CD erythrocytes_NNS with_IN micronuclei_NN was_VBD
          scored_VBN ._.
        
        
          RNA_NNP extraction_NN and_CC quantitative_JJ reverse_NN
          transcription-polymerase_JJ chain_NN reaction_NN
          All_DT heart_NN samples_NNS were_VBD immediately_RB frozen_VBN in_IN liquid_JJ
          nitrogen_NN for_IN RNA_NNP extraction_NN ._. RNA_NNP was_VBD extracted_VBN by_IN
          standard_JJ methods_NNS [_NN 29_CD ]_NN and_CC analyzed_VBN by_IN reverse_NN
          transcription_NN followed_VBN by_IN real-time_JJ quantitative_JJ
          polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) for_IN the_DT transcripts_NNS of_IN
          interest_NN ._. The_DT methodology_NN of_IN quantitative_JJ PCR_NNP has_VBZ been_VBN
          described_VBN in_IN detail_NN previously_RB [_NN 30_CD ]_NN ._. Specific_JJ
          quantitative_JJ assays_NNS were_VBD designed_VBN from_IN mouse_NN sequences_NNS
          available_JJ in_IN GenBank_NNP ™_NN ._. Primers_NNP and_CC probes_NNS were_VBD designed_VBN
          from_IN nonconserved_JJ sequences_NNS of_IN the_DT genes_NNS (_( allowing_VBG for_IN
          isoform_NN specificity_NN )_) ,_, spanning_VBG sites_NNS where_WRB two_CD exons_NNS join_VBP
          (_( splice_NN sites_NNS )_) when_WRB such_JJ sites_NNS are_VBP known_VBN (_( preventing_VBG
          recognition_NN of_IN the_DT assay_NN to_TO any_DT potential_JJ contaminating_VBG
          genomic_JJ DNA_NNP )_) ._. Standard_NNP RNA_NNP was_VBD made_VBN for_IN all_DT assays_NNS by_IN the_DT
          T_NN 7_CD polymerase_NN method_NN (_( Ambion_NNP ,_, Austin_NNP ,_, TX_NNP )_) ,_, using_VBG total_JJ
          RNA_NNP isolated_VBD from_IN the_DT mouse_NN heart_NN ._. The_DT correlation_NN
          between_IN the_DT C_NNP 
          t_NN (_( the_DT number_NN of_IN polymerase_NN chain_NN
          reaction_NN cycles_NNS required_VBN for_IN the_DT fluorescent_NN signal_NN to_TO
          reach_VB a_DT detection_NN threshold_NN )_) and_CC the_DT amount_NN of_IN standard_NN
          was_VBD linear_JJ over_IN at_IN least_JJS a_DT 5_CD -_: log_VB range_NN of_IN RNA_NNP for_IN all_DT
          assays_NNS (_( data_NNS not_RB shown_VBN )_) ._. The_DT level_NN of_IN transcripts_NNS for_IN the_DT
          constitutive_JJ gene_NN product_NN β-actin_JJ was_VBD quantitatively_RB
          measured_VBN in_IN each_DT sample_NN to_TO control_VB for_IN sample-to-sample_JJ
          differences_NNS in_IN RNA_NNP concentration_NN ._. Polymerase_NNP chain_NN
          reaction_NN data_NNS are_VBP reported_VBN as_IN the_DT number_NN of_IN
          transcripts_NNS /_NN number_NN of_IN β-actin_JJ molecules_NNS ._.
        
      
    
  
